Dumfries & Galloway Health Board
Prescribing Support Team

Denosumab shared care protocol

Posted: 5 Dec 16 Edited: 8 Aug 18
Guidelines Endocrine System


Denosumab is the first of a new class of agents for the treatment of osteoporosis. It is a fully human monoclonal antibody, which inhibits bone resorption by specifically targeting RANK Ligand in the bone matrix, thus mimicking the body’s natural bone protection mechanism. 5 year efficacy and safety data for use in postmenopausal osteoporosis - this document provides advice on prescribing of this product for GP practices